Sodium glucose co-transporter 2 inhibitors (SGLT2Is) effect on erectile dysfunction (ED) in patients with chronic kidney disease (CKD)
Abstract
BACKGROUND: ED is commonly encountered among male CKD patients. SGLT2Is were recently recommended as a universal treatment for CKD. It's hypothesized that the mechanism of action of SGLT2Is could be related to improving endothelial dysfunction. So, patients with ED due to CKD might benefit from adding SGLT2Is to their management. We aimed to study the effect of SGLT2Is on ED in CKD patients.
METHODS: After complete clinical examination and laboratory investigations needed to exclude other causes of ED, 34 CKD cases were randomly assigned to receive either empagliflozin (Empa) or dapagliflozin (Dapa). All selected candidates signed a written consent and were then referred to the Andrology clinic for assessment for ED. The structured questionnaire (International Index of Erectile Function) was used before starting and 3 months after use of the assigned SGLT2I.
RESULTS: Both SGLT2Is were associated with highly significant improvement in kidney function as well as IIEF-5 (P < 0.001 in all).
CONCLUSION: SGLT2Is improve endothelial function and correct pericyte depletion induced by uremia. The postulated mechanisms of action that improve erectile function are discussed.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.